ReviewSeminars in nephrology2024
Post-Transplant Lymphoproliferative Disorders.
Review in Seminars in nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients With Posttransplant Lymphoproliferative Disorder: A Single-Center Retrospective Study.Annals of transplantation · 2026Article
- Review
- Gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report.Clinical journal of gastroenterology · 2026Article
- Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development.Cell reports. Medicine · 2026Article
- Allograft-localized post-transplant lymphoproliferative disorder in a pediatric kidney transplant recipient: a case report and focused review.BMC pediatrics · 2026Review
- Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review.Frontiers in transplantation · 2026Review
- COVID-19 and Superimposed Aspergillosis in a Dual Organ Recipient with Diagnosed B-Cell Lymphoproliferative Disorder: A Rare Case Report and Literature Review.Diseases (Basel, Switzerland) · 2025Article
- Malignancies After Renal Transplantation: Frequency, Etiology, and Prognosis-A Single Center Experience.Journal of clinical medicine · 2025Article
- Utility ofAnnals of nuclear medicine · 2025Article
- Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2025Article
- The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study.Annals of internal medicine · 2025Article
- Case report: A rare EBV-associated T/NK cell monomorphic posttransplant lymphoproliferative disorder.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Post-transplant lymphoproliferative disorders (PTLDs) are a heterogenous set of unregulated lymphoid cell proliferations after organ or tissue transplant. A majority of cases are associated with the Epstein-Barr virus and higher intensity of pharmacologic immunosuppression. The clinical presentations are numerous. The diagnosis is ideally by histology, except in cases where the tumor is inaccessible to biopsy. While some pre-emptive therapies and treatment strategies are available have reasonable success are available, they do not eliminate the high morbidity and significant mortality after PTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.